Thu. 16 May 2024, 7:03am ET
Benzinga
Biotech, News, Health Care, General
- ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients
- ION582 was safe and well tolerated at all dose levels
- Ionis plans to move ION582 into pivotal trial
- Detailed ION582 data to be presented at upcoming medical meeting